Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016
Published Jun 22, 2016
110 pages — Published Jun 22, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016, provides in depth analysis on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  
Source:
Document ID
GMDHC0109TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Overview101
Therapeutics Development114
  Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Stage of Development111
  Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Therapy Area121
  Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Indication132
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Pipeline Products Glance152
  Late Stage Products151
  Early Stage Products161
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Companies175
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Products under Development by Universities/Institutes222
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Therapeutics Assessment245
  Assessment by Monotherapy/Combination Products241
  Assessment by Mechanism of Action251
  Assessment by Route of Administration262
  Assessment by Molecule Type281
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Companies Involved in Therapeutics Development2915
  Acetylon Pharmaceuticals, Inc.292
  Chong Kun Dang Pharmaceutical Corp.311
  HitGen LTD321
  Kancera AB331
  Karus Therapeutics Limited341
  Lycera Corp.351
  Merck &Co., Inc.361
  Millennium Pharmaceuticals, Inc.371
  OncoHoldings, Inc.381
  Quimatryx, S.L.391
  Sigma-Tau S.p.A.401
  SK Biopharmaceuticals Co., Ltd.411
  Takeda Pharmaceutical Company Limited421
  TetraLogic Pharmaceuticals431
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drug Profiles4444
  ACY-241 Drug Profile442
  ACY-738 Drug Profile461
  ACY-775 Drug Profile471
  C-1A Drug Profile481
  CKD-506 Drug Profile491
  CKD-L Drug Profile501
  Drugs to Inhibit HDAC6 for Oncology Drug Profile511
  HG-3001 Drug Profile521
  IKH-12 Drug Profile531
  KA-2507 Drug Profile541
  KAN-0439221 Drug Profile551
  KAN-439782 Drug Profile561
  KAR-3000 Drug Profile571
  N-140 Drug Profile581
  ONCO-101 Drug Profile591
  QTX-100 Drug Profile601
  QTX-102 Drug Profile611
  QTX-125 Drug Profile621
  remetinostat Drug Profile632
  ricolinostat Drug Profile657
  Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma Drug Profile721
  Small Molecule to Inhibit HDAC6 Drug Profile731
  Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease Drug Profile741
  Small Molecule to Inhibit HDAC6 for Oncology Drug Profile751
  Small Molecule to Inhibit HDAC6 for Sepsis Drug Profile761
  Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders Drug Profile771
  Small Molecules to Inhibit HDAC6 for Autoimmune Diseases Drug Profile781
  Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases Drug Profile791
  Small Molecules to Inhibit HDAC6 for Oncology Drug Profile801
  Small Molecules to Inhibit HDAC6 for Oncology and Immunology Drug Profile811
  Small Molecules to Inhibit Histone Deacetylase 6 for Oncology Drug Profile821
  ST-3595 Drug Profile831
  vorinostat Drug Profile844
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Dormant Projects882
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Featured News &Press Releases9019
  Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models901
  Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology911
  Dec 07, 2015: Acetylon Presents Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma922
  Dec 07, 2015: Acetylon Presents Data on the use of HDAC 6 Inhibitors Ricolinostat and ACY-241 in Combination with Pomalidomide for the Treatment of Multiple Myeloma942
  Nov 06, 2015: Acetylon's Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-tumor Activity of Paclitaxel in Preclinical Solid Tumor Models962
  Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata981
  Jun 15, 2015: Acetylon Pharmaceuticals Presented Positive Preliminary Data from Phase 1b/2 Trial of Ricolinostat in Combination with Pomalyst as Potential Oral Treatment for Patients with Multiple Myeloma981
  Apr 22, 2015: Acetylon Presents Data on Synergistic Activity of Selective HDAC6 Inhibition in Preclinical Models of Multiple Myeloma and Mantle Cell Lymphoma at the American Association for Cancer Research Annual Meeting991
  Jan 21, 2015: Acetylon Presents at the Wells Fargo Celgene Partnership Forum1001
  Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma1011
  Dec 09, 2014: Acetylon Pharmaceuticals Announces Ricolinostat Continues to Demonstrate Clinically Meaningful and Durable Disease Response Rates in Phase 1b Combination Studies in Multiple Myeloma1012
  Dec 04, 2014: Acetylon Pharmaceuticals Initiates Phase 2 Study of Ricolinostat (ACY-1215) in Combination with Pomalyst1031
  Dec 01, 2014: Acetylon s Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition1034
  Jun 13, 2014: Acetylon Pharmaceuticals Reports Ricolinostat (ACY-1215) is Active and Well-tolerated in Ongoing Phase 1b Studies in Patients with Refractory Multiple Myeloma at the 19th Congress of the EHA1071
  May 28, 2014: TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting1081
Appendix1092
  Methodology1091
  Coverage1091
  Secondary Research1091
  Primary Research1091
  Expert Panel Validation1091
  Contact Us1091
  Disclaimer1101

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Histone-Deacetylase-6-Protein-Phosphatase-1-Regulatory-Subunit-90-or-HDAC6-or-EC-3-5-1-98-Pipeline-Review-H1-2016-2088-16001>
  
APA:
Global Markets Direct - Market Research. (2016). Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Histone-Deacetylase-6-Protein-Phosphatase-1-Regulatory-Subunit-90-or-HDAC6-or-EC-3-5-1-98-Pipeline-Review-H1-2016-2088-16001>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.